PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-15.16%
Negative net income growth while Biotechnology median is -7.51%. Seth Klarman would suspect a firm-specific problem if peers maintain profit growth.
8.11%
D&A growth of 8.11% while Biotechnology median is zero at 0.00%. Walter Schloss would question intangible or new expansions driving that cost difference.
14.88%
Deferred tax growth of 14.88% while Biotechnology median is zero at 0.00%. Walter Schloss would see a difference that might matter for future cash flow if significant.
33.33%
SBC growth of 33.33% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or staff additions causing more equity grants.
-359.86%
Working capital is shrinking yoy while Biotechnology median is 0.00%. Seth Klarman would see an advantage if sales remain robust.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-185.03%
Other WC usage shrinks yoy while Biotechnology median is 0.00%. Seth Klarman would see an advantage if top-line is stable or growing.
-14.88%
Other non-cash items dropping yoy while Biotechnology median is 0.00%. Seth Klarman would see a short-term advantage if real fundamentals remain intact.
-25.31%
Negative CFO growth while Biotechnology median is 0.00%. Seth Klarman would suspect a firm-specific operational weakness if peers maintain growth.
-2962.50%
CapEx declines yoy while Biotechnology median is 0.00%. Seth Klarman would note a short-term FCF advantage if revenue is stable.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2962.50%
Reduced investing yoy while Biotechnology median is 0.00%. Seth Klarman sees potential advantage in near-term liquidity if revenue remains stable.
56.30%
Debt repayment growth of 56.30% while Biotechnology median is zero at 0.00%. Walter Schloss wonders if expansions or a shift in capital structure drive that difference.
23135.79%
Issuance growth of 23135.79% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or acquisitions financed by new shares.
100.00%
Buyback growth of 100.00% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or higher yoy CFO enabling that difference.